View ValuationSartorius 향후 성장Future 기준 점검 4/6Sartorius (는) 각각 연간 20.7% 및 8.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 16.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 17.4% 로 예상됩니다.핵심 정보20.7%이익 성장률16.16%EPS 성장률Life Sciences 이익 성장20.2%매출 성장률8.8%향후 자기자본이익률17.41%애널리스트 커버리지Good마지막 업데이트22 May 2026최근 향후 성장 업데이트공시 • Feb 05Sartorius AG Provides Earnings Guidance for the Fiscal Year 2026Sartorius AG provided earnings guidance for the fiscal year 2026. For the year, the company expects its profitable growth trajectory to continue, with a continued positive development in the Bioprocess Solutions Division and a recovery in the Lab Products & Services Division.공시 • Oct 17Sartorius Aktiengesellschaft Revises Financial Guidance for the Year 2025Sartorius Aktiengesellschaft revised financial guidance for the year 2025. Based on the year-to-date results and taking into account the anticipated impact of existing tariffs, the contributions from the MATTEK acquisition, as well as the strong basis for comparison in the fourth quarter of 2024, management further sharpens its full-year guidance for the Group and both divisions. The company now expects sales revenue growth at Group level of around 7% (previously: around 6% organic growth with a forecast range of about plus/minus two percentage points). This includes an inorganic growth contribution of around 0.3%.공시 • Apr 17Sartorius Aktiengesellschaft Provides Earnings Guidance for the Fiscal 2025Sartorius Aktiengesellschaft provided earnings guidance for the fiscal 2025. For the period, Based on the first quarter results and the expected good underlying market development, management projects sales revenue growth of around 6% for the Group, around 7% for the Bioprocess Solutions division and around 1% for Lab Products & Services for 2025. Due to the continued above-average volatility, the company currently anticipates a forecast range of about plus/minus two percentage points respectively.공시 • Oct 13Sartorius Ag Lowers Earnings Forecast for the Fiscal Year 2023SARTORIUS AG lowered earnings forecast for the fiscal year 2023. For the year, Group sales revenue is expected to decline by around 17 percent; excluding Covid-19-related business, revenue would decline by around 12% (previously: sales revenue decline in the low to mid-teens percentage range; excluding Covid-19-related business, decline in the mid to high single-digit percentage range). Acquisitions are still expected to contribute around 2 percentage points to the sales revenue development.공시 • Jan 27Sartorius Aktiengesellschaft Provides Revenue Guidance for the Full Year 2023Sartorius Aktiengesellschaft provided revenue guidance for the full year 2023. Consolidated sales revenue is expected to increase by an amount in the low single-digit percentage range. Excluding the Covid-19-related business, the increase would be in the high single-digit percentage range. Acquisitions are anticipated to contribute around 1% point to growth.Major Estimate Revision • Jul 28Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate increased from €9.25 to €10.20. Revenue forecast steady at €4.16b. Net income forecast to grow 35% next year vs 13% growth forecast for Medical Equipment industry in Germany. Consensus price target down from €416 to €404. Share price was steady at €389 over the past week.모든 업데이트 보기Recent updates공시 • Feb 17Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026, at 12:00 W. Europe Standard Time.공시 • Feb 07Sartorius Aktiengesellschaft announces Annual dividend, payable on March 31, 2026Sartorius Aktiengesellschaft announced Annual dividend of EUR 0.7400 per share payable on March 31, 2026, ex-date on March 27, 2026 and record date on March 30, 2026.공시 • Feb 05Sartorius AG Provides Earnings Guidance for the Fiscal Year 2026Sartorius AG provided earnings guidance for the fiscal year 2026. For the year, the company expects its profitable growth trajectory to continue, with a continued positive development in the Bioprocess Solutions Division and a recovery in the Lab Products & Services Division.공시 • Jan 28Sartorius Aktiengesellschaft to Report Fiscal Year 2025 Final Results on Feb 16, 2026Sartorius Aktiengesellschaft announced that they will report fiscal year 2025 final results at 12:00 PM, Central European Standard Time on Feb 16, 2026공시 • Jan 16Sartorius Expands Bio-Circular Product Offering for More Sustainable BioprocessesSartorius AG expanded bio-circular product offering for more sustainable bioprocesses. Further production hubs in Germany and Tunisia now certified by International Sustainability and Carbon Certification. Certified raw materials significantly reduce dependence on fossil-based plastics. Bio-circular filters and additional single-use fluid management technologies now available for biopharma manufacturers. Certified production network spans sites in Germany, Tunisia, France and the UK. With ISCC Plus certification now extended to its sites in Gottingen, Germany, and M'Hamdia, Tunisia, the company can use certified renewable raw materials in additional product lines, reducing the share of fossil-based plastics while ensuring full compatibility with existing bioprocesses. ISCC Plus is a global standard for renewable and recycled raw materials that ensures transparent and traceable sourcing and compliance across the value chain based on a mass-balance system. At its Gottingen headquarters, Sartorius will produce the PFAS-free filter Sartopore Evo using ISCC Plus-certified materials. In M'Hamdia, selected Flexsafe bags will be manufactured with certified second generation feedstock. The use of ISCC Plus-certified material enables a reduction of fossil-based compounds by around 70% in the Flexsafe film and by an average 40-60% in Sartopore Evo filters. Earlier in 2025, Sartorius achieved ISCC Plus certification for its sites in Aubagne, France, and Stonehouse, United Kingdom, covering its Ambr bioreactor vessels, Vivaflow filters, and selected Flexsafe bags for the manufacture of biopharmaceutical. The company plans to expand the use of certified renewable raw materials across its global production network.공시 • Dec 19+ 3 more updatesSartorius Aktiengesellschaft to Report Q1, 2026 Results on Apr 23, 2026Sartorius Aktiengesellschaft announced that they will report Q1, 2026 results on Apr 23, 2026공시 • Oct 17Sartorius Aktiengesellschaft Revises Financial Guidance for the Year 2025Sartorius Aktiengesellschaft revised financial guidance for the year 2025. Based on the year-to-date results and taking into account the anticipated impact of existing tariffs, the contributions from the MATTEK acquisition, as well as the strong basis for comparison in the fourth quarter of 2024, management further sharpens its full-year guidance for the Group and both divisions. The company now expects sales revenue growth at Group level of around 7% (previously: around 6% organic growth with a forecast range of about plus/minus two percentage points). This includes an inorganic growth contribution of around 0.3%.공시 • Jun 23+ 1 more updateSartorius Aktiengesellschaft(XTRA:SRT) dropped from FTSE All-World Index (USD)Sartorius Aktiengesellschaft(XTRA:SRT) dropped from FTSE All-World Index (USD)공시 • Apr 17Sartorius Aktiengesellschaft Provides Earnings Guidance for the Fiscal 2025Sartorius Aktiengesellschaft provided earnings guidance for the fiscal 2025. For the period, Based on the first quarter results and the expected good underlying market development, management projects sales revenue growth of around 6% for the Group, around 7% for the Bioprocess Solutions division and around 1% for Lab Products & Services for 2025. Due to the continued above-average volatility, the company currently anticipates a forecast range of about plus/minus two percentage points respectively.공시 • Mar 29Sartorius Ag Approves Ordinary Dividend, Payable on April 1, 2025Sartorius AG at its AGM held on March 27, 2025, approved the dividend of 0.73 euros per ordinary share. The total amount disbursed will be 50.7 million euros, with the dividend to be paid out to shareholders on April 1, 2025.공시 • Feb 18Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025.공시 • Feb 09Sartorius AG Proposes Ordinary Dividend for Fiscal 2024, Payable on April 1, 2025The Supervisory Board of Sartorius AG resolved at its meeting held on February 7, 2025 to approve the recommendation of the Executive Board to submit a proposal to the Annual General Meeting on March 27, 2025, to pay a dividend of EUR 0.73 per ordinary share for fiscal 2024, the same amount as for the previous year. The dividend will be paid on April 1, 2025.공시 • Jan 28+ 1 more updateSartorius Aktiengesellschaft to Report Nine Months, 2025 Results on Oct 16, 2025Sartorius Aktiengesellschaft announced that they will report nine months, 2025 results on Oct 16, 2025공시 • Jan 14+ 1 more updateSartorius Aktiengesellschaft to Report Fiscal Year 2024 Final Results on Feb 17, 2025Sartorius Aktiengesellschaft announced that they will report fiscal year 2024 final results on Feb 17, 2025공시 • Nov 16Sartorius Aktiengesellschaft to Report Fiscal Year 2024 Results on Jan 28, 2025Sartorius Aktiengesellschaft announced that they will report fiscal year 2024 results on Jan 28, 2025공시 • Sep 19Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3).Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024. Sartorius will become a shareholder in labforward GmbH post the transaction. The merged company will be led by Joerg Hoffmann of labforward GmbH. The future headquarters will be the previous location of LabTwin in Berlin. Labforward GmbH completed the acquisition of LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024.공시 • Feb 03Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Final Results on Feb 16, 2024Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 final results at 7:00 AM, Central European Standard Time on Feb 16, 2024공시 • Jan 26+ 2 more updatesSartorius Aktiengesellschaft to Report Q3, 2024 Results on Oct 17, 2024Sartorius Aktiengesellschaft announced that they will report Q3, 2024 results on Oct 17, 2024공시 • Jan 18Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Results on Jan 26, 2024Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 results at 7:00 AM, Central European Standard Time on Jan 26, 2024공시 • Oct 13Sartorius Ag Lowers Earnings Forecast for the Fiscal Year 2023SARTORIUS AG lowered earnings forecast for the fiscal year 2023. For the year, Group sales revenue is expected to decline by around 17 percent; excluding Covid-19-related business, revenue would decline by around 12% (previously: sales revenue decline in the low to mid-teens percentage range; excluding Covid-19-related business, decline in the mid to high single-digit percentage range). Acquisitions are still expected to contribute around 2 percentage points to the sales revenue development.공시 • Aug 06+ 1 more updateSartorius Announces Executive Board ChangesSartorius appointed Florian Funck as Member of the Sartorius Executive Board, effective April 1, 2024. Funck succeeds Rainer Lehmann, with whom it was agreed in early May 2023 that he would leave the Executive Board at his own request at the end of October 2023. Funck joins the company from his current role as CFO of the Haniel Group, where he has been working for more than two decades. Funck is also a member of the Supervisory Boards of Vonovia SE and the Haniel holdings TAKKT AG and Ceconomy AG. At Sartorius, in addition to finance, he will also be responsible for the IT and digitalization functions. After Lehmann's departure and until Funck takes over, Sartorius CEO Joachim Kreuzburg will assume the responsibilities on an interim basis.공시 • Jan 27Sartorius Aktiengesellschaft Provides Revenue Guidance for the Full Year 2023Sartorius Aktiengesellschaft provided revenue guidance for the full year 2023. Consolidated sales revenue is expected to increase by an amount in the low single-digit percentage range. Excluding the Covid-19-related business, the increase would be in the high single-digit percentage range. Acquisitions are anticipated to contribute around 1% point to growth.공시 • Jan 04Sartorius Announces Management Changes for Sartorius North AmericaSartorius announced Maurice Phelan has assumed the role of President of Sartorius North America. He succeeds Mary Lavin, who has retired after nearly 35 years. Sartorius North America, headquartered in Bohemia, New York, currently employs more than 3,000 employees across 17 sites in the United States and Canada. Mr. Phelan has spent many years in the industry and recently rejoined Sartorius from Repligen, where he was Vice President of Fluid Management. Before that, he served as Head of Operations of the Sartorius site in Marlborough, Massachusetts. Previously, he held leadership roles at GE Healthcare and Merck Millipore. Mr. Phelan holds degrees in chemistry and experimental physics from the National University of Ireland.공시 • Oct 20Sartorius Aktiengesellschaft to Report Fiscal Year 2022 Final Results on Feb 17, 2023Sartorius Aktiengesellschaft announced that they will report fiscal year 2022 final results on Feb 17, 2023공시 • Oct 19+ 2 more updatesSartorius Aktiengesellschaft to Report Nine Months, 2023 Results on Oct 19, 2023Sartorius Aktiengesellschaft announced that they will report nine months, 2023 results on Oct 19, 2023Major Estimate Revision • Jul 28Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate increased from €9.25 to €10.20. Revenue forecast steady at €4.16b. Net income forecast to grow 35% next year vs 13% growth forecast for Medical Equipment industry in Germany. Consensus price target down from €416 to €404. Share price was steady at €389 over the past week.Reported Earnings • Jul 22First quarter 2022 earnings releasedFirst quarter 2022 results: EPS: €3.01. Revenue: €1.02b (up 30% from 1Q 2021). Net income: €205.6m (up 128% from 1Q 2021). Profit margin: 20% (up from 11% in 1Q 2021). Over the next year, revenue is forecast to grow 16%, compared to a 7.9% growth forecast for the industry in Germany.Price Target Changed • Jul 22Price target decreased to €404Down from €444, the current price target is an average from 17 analysts. New target price is 5.1% above last closing price of €385. Stock is down 21% over the past year. The company is forecast to post earnings per share of €9.55 for next year compared to €4.66 last year.Price Target Changed • Jul 12Price target decreased to €416Down from €470, the current price target is an average from 17 analysts. New target price is 15% above last closing price of €363. Stock is down 26% over the past year. The company is forecast to post earnings per share of €8.83 for next year compared to €4.66 last year.Buying Opportunity • May 31Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 1.1%. The fair value is estimated to be €448, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings is also forecast to grow by 11% per annum over the same time period.Reported Earnings • Apr 27First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: EPS: €3.00. Revenue: €1.02b (up 30% from 1Q 2021). Net income: €205.6m (up 151% from 1Q 2021). Profit margin: 20% (up from 10% in 1Q 2021). Revenue exceeded analyst estimates by 7.8%. Earnings per share (EPS) also surpassed analyst estimates by 41%. Over the next year, revenue is forecast to grow 15%, compared to a 11% growth forecast for the industry in Germany.Upcoming Dividend • Mar 21Upcoming dividend of €1.25 per shareEligible shareholders must have bought the stock before 28 March 2022. Payment date: 30 March 2022. Payout ratio is a comfortable 27% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (3.6%). Lower than average of industry peers (1.1%).Valuation Update With 7 Day Price Move • Mar 08Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €304, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 31x in the Medical Equipment industry in Germany. Total returns to shareholders of 140% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €290 per share.Reported Earnings • Feb 18Full year 2021 earnings: Revenues exceed analyst expectationsFull year 2021 results: Revenue: €3.45b (up 48% from FY 2020). Net income: €318.9m (up 41% from FY 2020). Profit margin: 9.2% (in line with FY 2020). Revenue exceeded analyst estimates by 1.5%. Over the next year, revenue is forecast to grow 18%, compared to a 12% growth forecast for the industry in Germany.Valuation Update With 7 Day Price Move • Jan 10Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €416, the stock trades at a forward P/E ratio of 57x. Average forward P/E is 36x in the Medical Equipment industry in Germany. Total returns to shareholders of 326% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €292 per share.Reported Earnings • Oct 22Third quarter 2021 earnings releasedThe company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: €897.7m (up 44% from 3Q 2020). Net income: €105.6m (up 55% from 3Q 2020). Profit margin: 12% (in line with 3Q 2020).Price Target Changed • Jul 26Price target increased to €383Up from €355, the current price target is an average from 17 analysts. New target price is 20% below last closing price of €480. Stock is up 78% over the past year.Reported Earnings • Jul 24Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €838.1m (up 53% from 2Q 2020). Net income: €108.1m (up 219% from 2Q 2020). Profit margin: 13% (up from 6.2% in 2Q 2020). The increase in margin was driven by higher revenue.Reported Earnings • Apr 24First quarter 2021 earnings released: EPS €1.20The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €791.1m (up 55% from 1Q 2020). Net income: €82.0m (up 78% from 1Q 2020). Profit margin: 10% (up from 9.1% in 1Q 2020). The increase in margin was driven by higher revenue.Upcoming Dividend • Mar 22Upcoming Dividend of €0.70 Per ShareWill be paid on the 31st of March to those who are registered shareholders by the 29th of March. The trailing yield of 0.2% is below the top quartile of German dividend payers (3.3%), and is lower than industry peers (1.0%).Price Target Changed • Feb 23Price target raised to €331Up from €247, the current price target is an average from 16 analysts. The new target price is 23% below the current share price of €432. As of last close, the stock is up 108% over the past year.Reported Earnings • Feb 20Full year 2020 earnings released: EPS €3.31 (vs €2.29 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €2.34b (up 28% from FY 2019). Net income: €226.3m (up 44% from FY 2019). Profit margin: 9.7% (up from 8.6% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth.Is New 90 Day High Low • Jan 30New 90-day high: €370The company is up 14% from its price of €325 on 30 October 2020. The German market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 19% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €189 per share.Price Target Changed • Nov 25Price target raised to €247Up from €217, the current price target is an average from 16 analysts. The new target price is 23% below the current share price of €320. As of last close, the stock is up 87% over the past year.Is New 90 Day High Low • Oct 22New 90-day high: €331The company is up 22% from its price of €271 on 24 July 2020. The German market is down 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €173 per share.Is New 90 Day High Low • Oct 01New 90-day high: €303The company is up 22% from its price of €248 on 03 July 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €187 per share.이익 및 매출 성장 예측XTRA:SRT - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20284,5073857211,1261912/31/20274,1063305841,0152212/31/20263,752258443839223/31/20263,554163443887N/A12/31/20253,538155395837N/A9/30/20253,517134479874N/A6/30/20253,468104575919N/A3/31/20253,444967121,070N/A12/31/20243,38184566976N/A9/30/20243,32478479924N/A6/30/20243,34178350838N/A3/31/20243,312149144697N/A12/31/20233,396206294854N/A9/30/20233,608358215821N/A6/30/20233,850495204807N/A3/31/20234,053566182744N/A12/31/20224,175678212734N/A9/30/20224,035534175690N/A6/30/20223,880489243723N/A3/31/20223,683434414837N/A12/31/20213,449319466873N/A9/30/20213,183372422770N/A6/30/20212,908332439737N/A3/31/20212,617254350627N/A12/31/20202,336210271512N/A9/30/20202,151181312503N/A6/30/20201,989154227427N/A3/31/20201,901165171385N/A12/31/20191,827157N/A377N/A9/30/20191,768171N/A337N/A6/30/20191,702166N/A318N/A3/31/20191,637153N/A312N/A12/31/20181,566141N/A245N/A9/30/20181,518138N/A245N/A6/30/20181,460126N/A244N/A3/31/20181,426115N/A223N/A12/31/20171,405115N/A207N/A9/30/20171,37691N/A185N/A6/30/20171,37796N/A182N/A3/31/20171,341105N/A173N/A12/31/20161,300103N/A170N/A9/30/20161,25099N/A145N/A6/30/20161,205101N/A112N/A3/31/20161,15996N/A132N/A12/31/20151,11585N/A125N/A9/30/20151,07676N/A160N/A6/30/20151,00361N/A153N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: SRT 의 연간 예상 수익 증가율(20.7%)이 saving rate(1.9%)보다 높습니다.수익 vs 시장: SRT 의 연간 수익(20.7%)이 German 시장(17.1%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: SRT 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: SRT 의 수익(연간 8.8%)이 German 시장(연간 6.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: SRT 의 수익(연간 8.8%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: SRT의 자본 수익률은 3년 후 17.4%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 16:05종가2026/05/22 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Sartorius Aktiengesellschaft는 38명의 분석가가 다루고 있습니다. 이 중 22명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Charles PitmanBarclaysCharles PitmanBarclaysHarry GillisBerenberg35명의 분석가 더 보기
공시 • Feb 05Sartorius AG Provides Earnings Guidance for the Fiscal Year 2026Sartorius AG provided earnings guidance for the fiscal year 2026. For the year, the company expects its profitable growth trajectory to continue, with a continued positive development in the Bioprocess Solutions Division and a recovery in the Lab Products & Services Division.
공시 • Oct 17Sartorius Aktiengesellschaft Revises Financial Guidance for the Year 2025Sartorius Aktiengesellschaft revised financial guidance for the year 2025. Based on the year-to-date results and taking into account the anticipated impact of existing tariffs, the contributions from the MATTEK acquisition, as well as the strong basis for comparison in the fourth quarter of 2024, management further sharpens its full-year guidance for the Group and both divisions. The company now expects sales revenue growth at Group level of around 7% (previously: around 6% organic growth with a forecast range of about plus/minus two percentage points). This includes an inorganic growth contribution of around 0.3%.
공시 • Apr 17Sartorius Aktiengesellschaft Provides Earnings Guidance for the Fiscal 2025Sartorius Aktiengesellschaft provided earnings guidance for the fiscal 2025. For the period, Based on the first quarter results and the expected good underlying market development, management projects sales revenue growth of around 6% for the Group, around 7% for the Bioprocess Solutions division and around 1% for Lab Products & Services for 2025. Due to the continued above-average volatility, the company currently anticipates a forecast range of about plus/minus two percentage points respectively.
공시 • Oct 13Sartorius Ag Lowers Earnings Forecast for the Fiscal Year 2023SARTORIUS AG lowered earnings forecast for the fiscal year 2023. For the year, Group sales revenue is expected to decline by around 17 percent; excluding Covid-19-related business, revenue would decline by around 12% (previously: sales revenue decline in the low to mid-teens percentage range; excluding Covid-19-related business, decline in the mid to high single-digit percentage range). Acquisitions are still expected to contribute around 2 percentage points to the sales revenue development.
공시 • Jan 27Sartorius Aktiengesellschaft Provides Revenue Guidance for the Full Year 2023Sartorius Aktiengesellschaft provided revenue guidance for the full year 2023. Consolidated sales revenue is expected to increase by an amount in the low single-digit percentage range. Excluding the Covid-19-related business, the increase would be in the high single-digit percentage range. Acquisitions are anticipated to contribute around 1% point to growth.
Major Estimate Revision • Jul 28Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate increased from €9.25 to €10.20. Revenue forecast steady at €4.16b. Net income forecast to grow 35% next year vs 13% growth forecast for Medical Equipment industry in Germany. Consensus price target down from €416 to €404. Share price was steady at €389 over the past week.
공시 • Feb 17Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026, at 12:00 W. Europe Standard Time.
공시 • Feb 07Sartorius Aktiengesellschaft announces Annual dividend, payable on March 31, 2026Sartorius Aktiengesellschaft announced Annual dividend of EUR 0.7400 per share payable on March 31, 2026, ex-date on March 27, 2026 and record date on March 30, 2026.
공시 • Feb 05Sartorius AG Provides Earnings Guidance for the Fiscal Year 2026Sartorius AG provided earnings guidance for the fiscal year 2026. For the year, the company expects its profitable growth trajectory to continue, with a continued positive development in the Bioprocess Solutions Division and a recovery in the Lab Products & Services Division.
공시 • Jan 28Sartorius Aktiengesellschaft to Report Fiscal Year 2025 Final Results on Feb 16, 2026Sartorius Aktiengesellschaft announced that they will report fiscal year 2025 final results at 12:00 PM, Central European Standard Time on Feb 16, 2026
공시 • Jan 16Sartorius Expands Bio-Circular Product Offering for More Sustainable BioprocessesSartorius AG expanded bio-circular product offering for more sustainable bioprocesses. Further production hubs in Germany and Tunisia now certified by International Sustainability and Carbon Certification. Certified raw materials significantly reduce dependence on fossil-based plastics. Bio-circular filters and additional single-use fluid management technologies now available for biopharma manufacturers. Certified production network spans sites in Germany, Tunisia, France and the UK. With ISCC Plus certification now extended to its sites in Gottingen, Germany, and M'Hamdia, Tunisia, the company can use certified renewable raw materials in additional product lines, reducing the share of fossil-based plastics while ensuring full compatibility with existing bioprocesses. ISCC Plus is a global standard for renewable and recycled raw materials that ensures transparent and traceable sourcing and compliance across the value chain based on a mass-balance system. At its Gottingen headquarters, Sartorius will produce the PFAS-free filter Sartopore Evo using ISCC Plus-certified materials. In M'Hamdia, selected Flexsafe bags will be manufactured with certified second generation feedstock. The use of ISCC Plus-certified material enables a reduction of fossil-based compounds by around 70% in the Flexsafe film and by an average 40-60% in Sartopore Evo filters. Earlier in 2025, Sartorius achieved ISCC Plus certification for its sites in Aubagne, France, and Stonehouse, United Kingdom, covering its Ambr bioreactor vessels, Vivaflow filters, and selected Flexsafe bags for the manufacture of biopharmaceutical. The company plans to expand the use of certified renewable raw materials across its global production network.
공시 • Dec 19+ 3 more updatesSartorius Aktiengesellschaft to Report Q1, 2026 Results on Apr 23, 2026Sartorius Aktiengesellschaft announced that they will report Q1, 2026 results on Apr 23, 2026
공시 • Oct 17Sartorius Aktiengesellschaft Revises Financial Guidance for the Year 2025Sartorius Aktiengesellschaft revised financial guidance for the year 2025. Based on the year-to-date results and taking into account the anticipated impact of existing tariffs, the contributions from the MATTEK acquisition, as well as the strong basis for comparison in the fourth quarter of 2024, management further sharpens its full-year guidance for the Group and both divisions. The company now expects sales revenue growth at Group level of around 7% (previously: around 6% organic growth with a forecast range of about plus/minus two percentage points). This includes an inorganic growth contribution of around 0.3%.
공시 • Jun 23+ 1 more updateSartorius Aktiengesellschaft(XTRA:SRT) dropped from FTSE All-World Index (USD)Sartorius Aktiengesellschaft(XTRA:SRT) dropped from FTSE All-World Index (USD)
공시 • Apr 17Sartorius Aktiengesellschaft Provides Earnings Guidance for the Fiscal 2025Sartorius Aktiengesellschaft provided earnings guidance for the fiscal 2025. For the period, Based on the first quarter results and the expected good underlying market development, management projects sales revenue growth of around 6% for the Group, around 7% for the Bioprocess Solutions division and around 1% for Lab Products & Services for 2025. Due to the continued above-average volatility, the company currently anticipates a forecast range of about plus/minus two percentage points respectively.
공시 • Mar 29Sartorius Ag Approves Ordinary Dividend, Payable on April 1, 2025Sartorius AG at its AGM held on March 27, 2025, approved the dividend of 0.73 euros per ordinary share. The total amount disbursed will be 50.7 million euros, with the dividend to be paid out to shareholders on April 1, 2025.
공시 • Feb 18Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025.
공시 • Feb 09Sartorius AG Proposes Ordinary Dividend for Fiscal 2024, Payable on April 1, 2025The Supervisory Board of Sartorius AG resolved at its meeting held on February 7, 2025 to approve the recommendation of the Executive Board to submit a proposal to the Annual General Meeting on March 27, 2025, to pay a dividend of EUR 0.73 per ordinary share for fiscal 2024, the same amount as for the previous year. The dividend will be paid on April 1, 2025.
공시 • Jan 28+ 1 more updateSartorius Aktiengesellschaft to Report Nine Months, 2025 Results on Oct 16, 2025Sartorius Aktiengesellschaft announced that they will report nine months, 2025 results on Oct 16, 2025
공시 • Jan 14+ 1 more updateSartorius Aktiengesellschaft to Report Fiscal Year 2024 Final Results on Feb 17, 2025Sartorius Aktiengesellschaft announced that they will report fiscal year 2024 final results on Feb 17, 2025
공시 • Nov 16Sartorius Aktiengesellschaft to Report Fiscal Year 2024 Results on Jan 28, 2025Sartorius Aktiengesellschaft announced that they will report fiscal year 2024 results on Jan 28, 2025
공시 • Sep 19Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3).Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024. Sartorius will become a shareholder in labforward GmbH post the transaction. The merged company will be led by Joerg Hoffmann of labforward GmbH. The future headquarters will be the previous location of LabTwin in Berlin. Labforward GmbH completed the acquisition of LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024.
공시 • Feb 03Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Final Results on Feb 16, 2024Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 final results at 7:00 AM, Central European Standard Time on Feb 16, 2024
공시 • Jan 26+ 2 more updatesSartorius Aktiengesellschaft to Report Q3, 2024 Results on Oct 17, 2024Sartorius Aktiengesellschaft announced that they will report Q3, 2024 results on Oct 17, 2024
공시 • Jan 18Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Results on Jan 26, 2024Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 results at 7:00 AM, Central European Standard Time on Jan 26, 2024
공시 • Oct 13Sartorius Ag Lowers Earnings Forecast for the Fiscal Year 2023SARTORIUS AG lowered earnings forecast for the fiscal year 2023. For the year, Group sales revenue is expected to decline by around 17 percent; excluding Covid-19-related business, revenue would decline by around 12% (previously: sales revenue decline in the low to mid-teens percentage range; excluding Covid-19-related business, decline in the mid to high single-digit percentage range). Acquisitions are still expected to contribute around 2 percentage points to the sales revenue development.
공시 • Aug 06+ 1 more updateSartorius Announces Executive Board ChangesSartorius appointed Florian Funck as Member of the Sartorius Executive Board, effective April 1, 2024. Funck succeeds Rainer Lehmann, with whom it was agreed in early May 2023 that he would leave the Executive Board at his own request at the end of October 2023. Funck joins the company from his current role as CFO of the Haniel Group, where he has been working for more than two decades. Funck is also a member of the Supervisory Boards of Vonovia SE and the Haniel holdings TAKKT AG and Ceconomy AG. At Sartorius, in addition to finance, he will also be responsible for the IT and digitalization functions. After Lehmann's departure and until Funck takes over, Sartorius CEO Joachim Kreuzburg will assume the responsibilities on an interim basis.
공시 • Jan 27Sartorius Aktiengesellschaft Provides Revenue Guidance for the Full Year 2023Sartorius Aktiengesellschaft provided revenue guidance for the full year 2023. Consolidated sales revenue is expected to increase by an amount in the low single-digit percentage range. Excluding the Covid-19-related business, the increase would be in the high single-digit percentage range. Acquisitions are anticipated to contribute around 1% point to growth.
공시 • Jan 04Sartorius Announces Management Changes for Sartorius North AmericaSartorius announced Maurice Phelan has assumed the role of President of Sartorius North America. He succeeds Mary Lavin, who has retired after nearly 35 years. Sartorius North America, headquartered in Bohemia, New York, currently employs more than 3,000 employees across 17 sites in the United States and Canada. Mr. Phelan has spent many years in the industry and recently rejoined Sartorius from Repligen, where he was Vice President of Fluid Management. Before that, he served as Head of Operations of the Sartorius site in Marlborough, Massachusetts. Previously, he held leadership roles at GE Healthcare and Merck Millipore. Mr. Phelan holds degrees in chemistry and experimental physics from the National University of Ireland.
공시 • Oct 20Sartorius Aktiengesellschaft to Report Fiscal Year 2022 Final Results on Feb 17, 2023Sartorius Aktiengesellschaft announced that they will report fiscal year 2022 final results on Feb 17, 2023
공시 • Oct 19+ 2 more updatesSartorius Aktiengesellschaft to Report Nine Months, 2023 Results on Oct 19, 2023Sartorius Aktiengesellschaft announced that they will report nine months, 2023 results on Oct 19, 2023
Major Estimate Revision • Jul 28Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate increased from €9.25 to €10.20. Revenue forecast steady at €4.16b. Net income forecast to grow 35% next year vs 13% growth forecast for Medical Equipment industry in Germany. Consensus price target down from €416 to €404. Share price was steady at €389 over the past week.
Reported Earnings • Jul 22First quarter 2022 earnings releasedFirst quarter 2022 results: EPS: €3.01. Revenue: €1.02b (up 30% from 1Q 2021). Net income: €205.6m (up 128% from 1Q 2021). Profit margin: 20% (up from 11% in 1Q 2021). Over the next year, revenue is forecast to grow 16%, compared to a 7.9% growth forecast for the industry in Germany.
Price Target Changed • Jul 22Price target decreased to €404Down from €444, the current price target is an average from 17 analysts. New target price is 5.1% above last closing price of €385. Stock is down 21% over the past year. The company is forecast to post earnings per share of €9.55 for next year compared to €4.66 last year.
Price Target Changed • Jul 12Price target decreased to €416Down from €470, the current price target is an average from 17 analysts. New target price is 15% above last closing price of €363. Stock is down 26% over the past year. The company is forecast to post earnings per share of €8.83 for next year compared to €4.66 last year.
Buying Opportunity • May 31Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 1.1%. The fair value is estimated to be €448, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings is also forecast to grow by 11% per annum over the same time period.
Reported Earnings • Apr 27First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: EPS: €3.00. Revenue: €1.02b (up 30% from 1Q 2021). Net income: €205.6m (up 151% from 1Q 2021). Profit margin: 20% (up from 10% in 1Q 2021). Revenue exceeded analyst estimates by 7.8%. Earnings per share (EPS) also surpassed analyst estimates by 41%. Over the next year, revenue is forecast to grow 15%, compared to a 11% growth forecast for the industry in Germany.
Upcoming Dividend • Mar 21Upcoming dividend of €1.25 per shareEligible shareholders must have bought the stock before 28 March 2022. Payment date: 30 March 2022. Payout ratio is a comfortable 27% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (3.6%). Lower than average of industry peers (1.1%).
Valuation Update With 7 Day Price Move • Mar 08Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €304, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 31x in the Medical Equipment industry in Germany. Total returns to shareholders of 140% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €290 per share.
Reported Earnings • Feb 18Full year 2021 earnings: Revenues exceed analyst expectationsFull year 2021 results: Revenue: €3.45b (up 48% from FY 2020). Net income: €318.9m (up 41% from FY 2020). Profit margin: 9.2% (in line with FY 2020). Revenue exceeded analyst estimates by 1.5%. Over the next year, revenue is forecast to grow 18%, compared to a 12% growth forecast for the industry in Germany.
Valuation Update With 7 Day Price Move • Jan 10Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €416, the stock trades at a forward P/E ratio of 57x. Average forward P/E is 36x in the Medical Equipment industry in Germany. Total returns to shareholders of 326% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €292 per share.
Reported Earnings • Oct 22Third quarter 2021 earnings releasedThe company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: €897.7m (up 44% from 3Q 2020). Net income: €105.6m (up 55% from 3Q 2020). Profit margin: 12% (in line with 3Q 2020).
Price Target Changed • Jul 26Price target increased to €383Up from €355, the current price target is an average from 17 analysts. New target price is 20% below last closing price of €480. Stock is up 78% over the past year.
Reported Earnings • Jul 24Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €838.1m (up 53% from 2Q 2020). Net income: €108.1m (up 219% from 2Q 2020). Profit margin: 13% (up from 6.2% in 2Q 2020). The increase in margin was driven by higher revenue.
Reported Earnings • Apr 24First quarter 2021 earnings released: EPS €1.20The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €791.1m (up 55% from 1Q 2020). Net income: €82.0m (up 78% from 1Q 2020). Profit margin: 10% (up from 9.1% in 1Q 2020). The increase in margin was driven by higher revenue.
Upcoming Dividend • Mar 22Upcoming Dividend of €0.70 Per ShareWill be paid on the 31st of March to those who are registered shareholders by the 29th of March. The trailing yield of 0.2% is below the top quartile of German dividend payers (3.3%), and is lower than industry peers (1.0%).
Price Target Changed • Feb 23Price target raised to €331Up from €247, the current price target is an average from 16 analysts. The new target price is 23% below the current share price of €432. As of last close, the stock is up 108% over the past year.
Reported Earnings • Feb 20Full year 2020 earnings released: EPS €3.31 (vs €2.29 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €2.34b (up 28% from FY 2019). Net income: €226.3m (up 44% from FY 2019). Profit margin: 9.7% (up from 8.6% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth.
Is New 90 Day High Low • Jan 30New 90-day high: €370The company is up 14% from its price of €325 on 30 October 2020. The German market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 19% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €189 per share.
Price Target Changed • Nov 25Price target raised to €247Up from €217, the current price target is an average from 16 analysts. The new target price is 23% below the current share price of €320. As of last close, the stock is up 87% over the past year.
Is New 90 Day High Low • Oct 22New 90-day high: €331The company is up 22% from its price of €271 on 24 July 2020. The German market is down 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €173 per share.
Is New 90 Day High Low • Oct 01New 90-day high: €303The company is up 22% from its price of €248 on 03 July 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €187 per share.